Richard J. Gryglewski

Richard J. Gryglewski's AcademicInfluence.com Rankings

Medical

#2792

World Rank

#3227

Historical Rank

Pharmacology

#311

World Rank

#361

Historical Rank

medical Degrees

Richard J. Gryglewski

Philosophy

#7977

World Rank

#11270

Historical Rank

Ontology

#91

World Rank

#102

Historical Rank

Logic

#5008

World Rank

#6361

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Richard J. Gryglewski's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is Richard J. Gryglewski Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard J. Gryglewski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation (1976) (3173)
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor (1986) (2461)
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. (1976) (997)
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. (1976) (949)
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. (1976) (594)
Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. (1975) (456)
On the mechanism of antithrombotic action of flavonoids. (1987) (429)
Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pig. (1975) (341)
SUCCESSFUL THERAPY OF ADVANCED ARTERIOSCLEROSIS OBLITERANS WITH PROSTACYCLIN (1979) (283)
Bioassay of prostacyclin and endothelium‐derived relaxing factor (EDRF) from porcine aortic endothelial cells (1997) (243)
Mechanism of action of some inhibitors of endothelium-derived relaxing factor. (1986) (212)
Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. (1978) (186)
Flavonoids and nitric oxide synthase. (2002) (160)
Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation. (1979) (152)
Thromboxane Generation and Platelet Aggregation in Survivals of Myocardial Infarction (1978) (130)
Dietary Supplementation with Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability (1985) (117)
Regulation of cyclooxygenase by the heme-heme oxygenase system in microvessel endothelial cells. (2002) (109)
Involvement of nitric oxide in the endothelium‐dependent relaxation induced by hydrogen peroxide in the rabbit aorta (1993) (95)
Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man (1978) (90)
Generation of prostaglandin E‐like material by the guinea‐pig trachea contracted by histamine (1975) (89)
Treatment of ischaemic stroke with prostacyclin. (1983) (83)
Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. (1993) (76)
Prostacyclin as a circulatory hormone. (1979) (73)
Steroid hormones, anti-inflammatory steroids and prostaglandins. (1976) (71)
Anti‐atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase‐1 (2009) (70)
Serum lipoproteins, lipid peroxides and prostacyclin biosynthesis in patients with coronary heart disease. (1981) (66)
Prostacyclin therapy in peripheral arterial disease. (1980) (60)
Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. (2005) (58)
Selective inhibition of thromboxane A2 biosynthesis in blood platelets (1977) (57)
Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells. (2002) (47)
Thrombolytic action of ticlopidine: possible mechanisms. (1996) (43)
Preparation and biochemical properties of PGH3. (1979) (43)
PROSTACYCLIN IN CENTRAL RETINAL VEIN OCCLUSION (1980) (41)
Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps. (1977) (39)
No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors. (2002) (37)
Platelet aggregability, thromboxane A2 and malonaldehyde formation following administration of aspirin to man. (1979) (34)
Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. (1994) (34)
Asthma relieved by aspirin and by other cyclo-oxygenase inhibitors. (1978) (32)
Double-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke. (1985) (32)
Thienopyridines: effects on cultured endothelial cells. (1999) (31)
Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. (2000) (29)
Aspirin-induced asthma. Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymic preparations. (1976) (29)
Obligatory role of lipid mediators in platelet-neutrophil adhesion. (2003) (28)
Asthmatic attacks induced in aspirin-sensitive patients by diclofenac and naproxen. (1977) (28)
Screening and Assessment of the Potency of Anti-Inflammatory Drugs in vitro (1979) (28)
Endogenous mechanisms that regulate prostacyclin release. (1980) (24)
Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats. (2003) (23)
Platelet aggregation and thromboxane A2 formation in cat platelet rich plasma. (1978) (23)
Synthesis and thrombolytic activity of new thienopyrimidinone derivatives. (2002) (21)
Angiotensin-induced release of prostacyclin from perfused organs. (1980) (21)
Generation of Prostaglandin and Thromboxane-Like Substances by Large Airways and Lung Parenchyma (1977) (19)
The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats (1994) (19)
Reversal of the postischaemic suppression of coronary function in perfused guinea pig heart by ischaemic preconditioning. (1999) (19)
Clinical use of prostacyclin (PGI2) in ischaemic stroke. (1982) (19)
Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins. (1995) (18)
Endogenous mechanisms which regulate prostacyclin release. (1979) (18)
Thrombolysis by thienopyridines and their congeners. (2000) (17)
Nitric oxide is a major mediator in reactive hyperaemia evoked by a brief coronary occlusion in the guinea pig heart. (1993) (17)
Biphasic response to lipopolysaccharide from E. coli in the isolated ventilated blood-perfused rat lung. (1999) (17)
Release of prostaglandin E‐like material from perfused mesenteric blood vessels of rabbits (1976) (17)
The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor. (1995) (16)
An abnormality of arachidonic acid metabolism is not a generalized phenomenon in patients with aspirin-induced asthma. (1988) (16)
Effects of endothelin-1 and endothelin-3 on the release of prostanoids from isolated perfused rat kidney. (1991) (16)
Polyunsaturated fatty acids and thrombosis (1979) (15)
Aspirin-Sensitive Asthma: Its Relationship to Inhibition of Prostaglandin Biosynthesis (1977) (15)
Lungs as a generator of prostacyclin — Hypothesis on physiological significance (1978) (13)
Release of prostacyclin by the lung. (1981) (13)
Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease. (1993) (12)
L-arginine--substrate for no synthesis--its beneficial effects in therapy of patients with peripheral arterial disease: comparison with placebo-preliminary results. (1996) (12)
Clonidine-induced coronary vasodilatation in isolated guinea pig heart is not mediated by endothelial alpha2 adrenoceptors. (2003) (12)
Dihomo-γ-Linolenic Acid in Patients with Atherosclerosis: Effects on Platelet Aggregation, Plasma Lipids and Low-Density Lipoprotein-Induced Inhibition of Prostacyclin Generation-Reply (1984) (11)
The endothelium-dependent and the endothelium-independent vasodilators in the isolated, perfused guinea pig heart. (1992) (11)
Prostacyclin and the mechanism of action of defibrotide. (1989) (11)
Carboxyebselen a potent and selective inhibitor of endothelial nitric oxide synthase. (1994) (11)
beta-Pyridylcarbinol (Ronicol) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. (1983) (10)
Arachidonic acid-induced platelet aggregation and thromboxane A2 generation in patients with coronary heart disease. (1978) (10)
Mechanisms of the Endothelium‐Dependent Relaxation Induced by NG‐Hydroxy‐L‐Arginine (1992) (10)
Paradoxical augmentation of bradykinin-induced vasodilatation by xanthine/xanthine oxidase-derived free radicals in isolated guinea pig heart. (2002) (10)
L-N6-(1-iminoethyl)-lysine (L-NIL) but not S-methylisothiourea sulphate (SMT) displays selectivity towards NOS-2. (1999) (9)
Endothelial Secretory Function and Atherothrombosis (2004) (8)
Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms. (1998) (7)
On the Mechanism of Thrombolytic Action of Thromboxane Synthetase Inhibitors (1987) (7)
Fibrinolytic Activity and the Effects of Beta-Pyridylcarbinol (Ronicol) in Patients with Arteriosclerosis Obliterans (1983) (7)
Beneficial results of pentoxifylline ('Trental') therapy in arteriosclerosis obliterans: possible mechanism of action. (1985) (7)
Effects of two beta3-agonists, CGP 12177A and BRL 37344, on coronary flow and contractility in isolated guinea pig heart. (2003) (7)
Effect of ticlopidine on streptokinase-induced thrombolysis in rats. (1999) (7)
Secretory function of vascular endothelium. (1987) (7)
Eosinophil-epithelial cell interaction augments cysteinyl leukotrienes synthesis. (2002) (6)
Action of beta-adrenolytics on the isolated guinea-pig atria. (1971) (6)
The dual action of meclofenamate on the contractile response to PGF2 alpha in the guinea-pig trachea. (1975) (6)
Plasma ANP and cyclic GMP after physical exercise in patients with mitral valve disease and in healthy subjects. (1993) (5)
Myocardial necroses produced by intravenous infusion of isoprenaline into rats (1971) (5)
Thrombolytic activity of beta-adrenolytic drug, sotalol. (1998) (5)
Chapter 3 The prostacyclins (1983) (5)
Some experimental models for the study of inflammation and anti-inflammatory drugs. (1977) (4)
Aspirin, prostaglandins, and bronchial asthma. (1980) (4)
[The effect of treatment with sulphur water from the spring in Wiesław in Busko-Solec on levels of lipids,the fibrinolytic system and thrombogenic platelet function in patients with arteriosclerosis]. (1997) (4)
Prostaglandin synthetase activity in the renal medulla of normal and hypertensive rats. (1974) (4)
INTERLEUKIN 1β INDUCES FUNCTIONAL PROSTAGLANDIN E SYNTHASE IN CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (2002) (4)
Prostacyclin and vascular disease. (1981) (4)
Effect of corticosteroids on the release of histamine and prostaglandins from fragments of mesentery of immunized guinea pigs. (1978) (4)
Role of thromboxane A2 and platelet activating factor in early haemodynamic response to lipopolysaccharide in rats. (1999) (4)
Increased pneumotoxicity of lipopolysaccharide from E.coli in nitric oxide deficient blood-perfused rat lungs. (1997) (4)
Bioassay of prostacyclin and endothelium‐derived relaxing factor (EDRF) from porcine aortic endothelial cells (1986) (3)
[Use of prostacyclin in patients with ischemic stroke. A double-blind method II]. (1988) (3)
Vasorelaxant and platelet-suppressant potencies of four NO-donors. (1990) (3)
Regulatory role of prostaglandins in the vascular system. (1975) (3)
Endothelium-derived relaxing factor (EDRF) from cultured and fresh endothelial cells. (1988) (3)
Aspirin sensitive asthma and arachidonic acid transformation. (1986) (3)
Stimulatory cholinergic effect on the release of antiaggregatory activity into the circulation of cat and man and its modification by β‐adrenergic antagonists (1985) (2)
Asthma and nonsteroidal anti-inflammatory drugs. (1979) (2)
[Prostacyclin in treatment of peripheral vascular disease of lower extremities (author's transl)]. (1980) (2)
Kinins and thrombolysis. (1993) (2)
Prostaglandin-like substances inPropionibacterium acnes. V. Activity profiles using cascade superfusion bioassay and platelet aggregation (1981) (2)
Haemodynamic and antihypertensive effect of prostacyclin. (1984) (2)
Effect of glucocorticosteroids on the release of prostaglandin-like substances in anaphylaxis. (1977) (1)
DIHOMO-γ- Linolenic Acid in Patients with Atherosclerosis ; Effects on Platelets, Plasma Lipids and LDL-Induced Inhibition of Prostacyclin Generation (1983) (1)
Asthma and Anti-inflammatory Drugs (1983) (1)
Anti-Platelet and Vasodilatory Action of Prostacyclin /PGI2/ in Healthy Men and in Patients with Peripheral Artery Disease (1979) (1)
Bioassay of prostacyclin and endothelium‐derived relaxing factor (EDRF) from porcine aortic endothelial cells (1997) (1)
Residual pulmonary neutrophils are involved in vaso- and bronchoconstrictor responses to platelet activating factor in the isolated buffer-perfused rat lung. (2000) (1)
Prostacyclin in the therapy of peripheral arterial disease. (1980) (1)
Pharmacological properties of a new beta-blocking agent (1-isopropylamino-3-(2-methyl-3-nitrophenoxy)-propan-2-ol). (1974) (1)
Dihomo-γ-Linolenic Acid in Patients with Atherosclerosis: Effects on Platelet Aggregation, Plasma Lipids and Low-Density Lipoprotein-Induced Inhibition of Prostacyclin Generation (1984) (1)
Clinical Use of Prostacyclin in Vascular Disease (1983) (1)
A new circulatory hormone: prostacyclin. (1978) (1)
[Almitrine, a powerful liberator of prostacyclin in vivo]. (1980) (0)
[The lung, producer of prostacyclin]. (1980) (0)
Dynamics of myocardial damage by isoprenaline in rats and an attempt to correlate the morphologic changes in the myocardium with electrocardiographic, biochemical and hematologic changes. (1971) (0)
Controlled trials on the effects of prostacyclin in vascular disease (1984) (0)
Evolution of ideas on the role of prostaglandins in inflammation. (1980) (0)
Regulation of Prostacyclin (PGI2) Release into Circulation (1982) (0)
Two main biological effects of prostacyclin, i.e., its effect (1983) (0)
An experimental model of micronecrosis in the myocardium in rats. (1971) (0)
Thrombolytic and Hypotensive Properties of Kallikrein in Anaesthetized Cats (1988) (0)
[Effect of prostacyclin (PGI2) on retinal arteries]. (1984) (0)
Aspirin, prostaglandins and bronchial asthma [proceedings]. (1978) (0)
The influence of corticosteroids on prostaglandin release from various organs. (1978) (0)
THE EFFECT OF SIX PROSTAGLANDINS, PROSTACYCLIN AND ILOPROST ON GENERATION OF SUPEROXIDE ANIONS (0J) BY HUMAN NEUTROPHILS (PMNs) ACTIVATED BY ZYMOSAN OR FMLP (1987) (0)
[Effect of prostacycline aerosol on the activity of blood platelets and lungs]. (1979) (0)
[Prostacyclin in ischemic stroke]. (1983) (0)
Kallikrein-thrombolytic and hypotensive action in cats--preliminary results. (1990) (0)
[Comparative studies on the damaging effect of catecholamines on rat myocardium]. (1976) (0)
Selective inhibition by fenflumizole tissue cyclooxygenase in rabbits ex vivo. (1985) (0)
Protection against isoprenaline induced myocardial necroses by beta-adrenergic blocking agents. (1973) (0)
Effects of Two &bgr;3-Agonists, CGP 12177A and BRL 37344, on Coronary Flow and Contractility in Isolated Guinea Pig Heart (2003) (0)
[1st intravenous administration of prostacyclin to man]. (1978) (0)
A new endocrine-like function of lungs: generation of prostacyclin. (1978) (0)

This paper list is powered by the following services:

Richard J. Gryglewski's Academic­Influence.com Rankings

Richard J. Gryglewski's Degrees

Why Is Richard J. Gryglewski Influential?

Richard J. Gryglewski's Published Works

Published Works

Richard J. Gryglewski's AcademicInfluence.com Rankings